nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—kidney cancer—bone cancer	0.24	0.509	CtDrD
Erlotinib—lung cancer—bone cancer	0.231	0.491	CtDrD
Erlotinib—NR1I2—bone cancer	0.202	0.575	CbGaD
Erlotinib—EGFR—bone cancer	0.11	0.312	CbGaD
Erlotinib—CYP3A4—bone cancer	0.0401	0.114	CbGaD
Erlotinib—CYP1B1—Doxorubicin—bone cancer	0.0189	0.215	CbGbCtD
Erlotinib—ABCG2—Carboplatin—bone cancer	0.0157	0.178	CbGbCtD
Erlotinib—ABCG2—Cisplatin—bone cancer	0.0134	0.153	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—bone cancer	0.00901	0.102	CbGbCtD
Erlotinib—ABCG2—Methotrexate—bone cancer	0.00872	0.099	CbGbCtD
Erlotinib—ALB—Methotrexate—bone cancer	0.00601	0.0683	CbGbCtD
Erlotinib—ABCB1—Cisplatin—bone cancer	0.00485	0.055	CbGbCtD
Erlotinib—ABCB1—Doxorubicin—bone cancer	0.00325	0.0369	CbGbCtD
Erlotinib—ABCB1—Methotrexate—bone cancer	0.00315	0.0357	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—bone cancer	0.00306	0.0347	CbGbCtD
Erlotinib—CYP3A4—Doxorubicin—bone cancer	0.00195	0.0221	CbGbCtD
Erlotinib—Gefitinib—CHEK2—bone cancer	0.00121	0.472	CrCbGaD
Erlotinib—Vandetanib—EGFR—bone cancer	0.00051	0.198	CrCbGaD
Erlotinib—Gefitinib—EGFR—bone cancer	0.000484	0.188	CrCbGaD
Erlotinib—ABL1—Idarubicin—Epirubicin—bone cancer	0.000275	0.173	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—bone cancer	0.000275	0.173	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—bone cancer	0.000275	0.173	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—bone cancer	0.000255	0.16	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—bone cancer	0.000255	0.16	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—bone cancer	0.000255	0.16	CbGdCrCtD
Erlotinib—Vandetanib—CYP3A4—bone cancer	0.000186	0.0724	CrCbGaD
Erlotinib—Gefitinib—CYP3A4—bone cancer	0.000177	0.0688	CrCbGaD
Erlotinib—Skin exfoliation—Doxorubicin—bone cancer	0.000133	0.00318	CcSEcCtD
Erlotinib—Mediastinal disorder—Cisplatin—bone cancer	0.000133	0.00317	CcSEcCtD
Erlotinib—Arrhythmia—Cisplatin—bone cancer	0.000132	0.00314	CcSEcCtD
Erlotinib—Neuropathy—Doxorubicin—bone cancer	0.000131	0.00313	CcSEcCtD
Erlotinib—Sepsis—Epirubicin—bone cancer	0.000131	0.00312	CcSEcCtD
Erlotinib—Alopecia—Cisplatin—bone cancer	0.000131	0.00311	CcSEcCtD
Erlotinib—Hepatic failure—Methotrexate—bone cancer	0.00013	0.00311	CcSEcCtD
Erlotinib—Dry eye—Doxorubicin—bone cancer	0.000129	0.00308	CcSEcCtD
Erlotinib—Erythema—Cisplatin—bone cancer	0.000129	0.00306	CcSEcCtD
Erlotinib—Malnutrition—Cisplatin—bone cancer	0.000129	0.00306	CcSEcCtD
Erlotinib—Renal failure acute—Methotrexate—bone cancer	0.000127	0.00302	CcSEcCtD
Erlotinib—Flatulence—Cisplatin—bone cancer	0.000127	0.00302	CcSEcCtD
Erlotinib—Hepatic failure—Epirubicin—bone cancer	0.000122	0.00291	CcSEcCtD
Erlotinib—Sepsis—Doxorubicin—bone cancer	0.000121	0.00289	CcSEcCtD
Erlotinib—Cerebrovascular accident—Methotrexate—bone cancer	0.00012	0.00285	CcSEcCtD
Erlotinib—Renal failure acute—Epirubicin—bone cancer	0.000119	0.00283	CcSEcCtD
Erlotinib—Renal impairment—Epirubicin—bone cancer	0.000115	0.00274	CcSEcCtD
Erlotinib—Dermatitis bullous—Epirubicin—bone cancer	0.000115	0.00273	CcSEcCtD
Erlotinib—Hepatic failure—Doxorubicin—bone cancer	0.000113	0.00269	CcSEcCtD
Erlotinib—Cerebrovascular accident—Epirubicin—bone cancer	0.000112	0.00267	CcSEcCtD
Erlotinib—Renal failure acute—Doxorubicin—bone cancer	0.00011	0.00262	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.00011	0.00261	CcSEcCtD
Erlotinib—Myalgia—Cisplatin—bone cancer	0.000109	0.00261	CcSEcCtD
Erlotinib—Anxiety—Cisplatin—bone cancer	0.000109	0.0026	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000109	0.00259	CcSEcCtD
Erlotinib—Renal impairment—Doxorubicin—bone cancer	0.000107	0.00254	CcSEcCtD
Erlotinib—Dermatitis bullous—Doxorubicin—bone cancer	0.000106	0.00253	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000106	0.00251	CcSEcCtD
Erlotinib—Oedema—Cisplatin—bone cancer	0.000105	0.0025	CcSEcCtD
Erlotinib—Infection—Cisplatin—bone cancer	0.000104	0.00248	CcSEcCtD
Erlotinib—Cerebrovascular accident—Doxorubicin—bone cancer	0.000104	0.00247	CcSEcCtD
Erlotinib—Nervous system disorder—Cisplatin—bone cancer	0.000103	0.00245	CcSEcCtD
Erlotinib—Thrombocytopenia—Cisplatin—bone cancer	0.000103	0.00245	CcSEcCtD
Erlotinib—Dehydration—Epirubicin—bone cancer	0.000102	0.00243	CcSEcCtD
Erlotinib—Skin disorder—Cisplatin—bone cancer	0.000102	0.00243	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000101	0.00242	CcSEcCtD
Erlotinib—Dry skin—Epirubicin—bone cancer	0.000101	0.00239	CcSEcCtD
Erlotinib—Anorexia—Cisplatin—bone cancer	0.0001	0.00238	CcSEcCtD
Erlotinib—Hypokalaemia—Epirubicin—bone cancer	9.98e-05	0.00238	CcSEcCtD
Erlotinib—Pancreatitis—Methotrexate—bone cancer	9.93e-05	0.00237	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Epirubicin—bone cancer	9.88e-05	0.00235	CcSEcCtD
Erlotinib—Gastritis—Epirubicin—bone cancer	9.71e-05	0.00231	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Epirubicin—bone cancer	9.67e-05	0.0023	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Cisplatin—bone cancer	9.56e-05	0.00228	CcSEcCtD
Erlotinib—Dysphagia—Epirubicin—bone cancer	9.48e-05	0.00226	CcSEcCtD
Erlotinib—Neutropenia—Methotrexate—bone cancer	9.47e-05	0.00226	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—bone cancer	9.44e-05	0.00225	CcSEcCtD
Erlotinib—Dyspnoea—Cisplatin—bone cancer	9.36e-05	0.00223	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—bone cancer	9.3e-05	0.00222	CcSEcCtD
Erlotinib—Pancreatitis—Epirubicin—bone cancer	9.29e-05	0.00221	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—bone cancer	9.23e-05	0.0022	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—bone cancer	9.14e-05	0.00218	CcSEcCtD
Erlotinib—Decreased appetite—Cisplatin—bone cancer	9.12e-05	0.00217	CcSEcCtD
Erlotinib—Pneumonia—Methotrexate—bone cancer	9.08e-05	0.00216	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Cisplatin—bone cancer	9.06e-05	0.00216	CcSEcCtD
Erlotinib—Infestation—Methotrexate—bone cancer	9.03e-05	0.00215	CcSEcCtD
Erlotinib—Infestation NOS—Methotrexate—bone cancer	9.03e-05	0.00215	CcSEcCtD
Erlotinib—Depression—Methotrexate—bone cancer	9e-05	0.00214	CcSEcCtD
Erlotinib—Gastritis—Doxorubicin—bone cancer	8.98e-05	0.00214	CcSEcCtD
Erlotinib—Pain—Cisplatin—bone cancer	8.98e-05	0.00214	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Methotrexate—bone cancer	8.95e-05	0.00213	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—bone cancer	8.95e-05	0.00213	CcSEcCtD
Erlotinib—Renal failure—Methotrexate—bone cancer	8.88e-05	0.00211	CcSEcCtD
Erlotinib—Neutropenia—Epirubicin—bone cancer	8.86e-05	0.00211	CcSEcCtD
Erlotinib—Stomatitis—Methotrexate—bone cancer	8.8e-05	0.0021	CcSEcCtD
Erlotinib—Conjunctivitis—Methotrexate—bone cancer	8.78e-05	0.00209	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—bone cancer	8.77e-05	0.00209	CcSEcCtD
Erlotinib—Pancreatitis—Doxorubicin—bone cancer	8.6e-05	0.00205	CcSEcCtD
Erlotinib—Weight decreased—Epirubicin—bone cancer	8.58e-05	0.00204	CcSEcCtD
Erlotinib—Hepatobiliary disease—Methotrexate—bone cancer	8.54e-05	0.00203	CcSEcCtD
Erlotinib—Epistaxis—Methotrexate—bone cancer	8.52e-05	0.00203	CcSEcCtD
Erlotinib—Pneumonia—Epirubicin—bone cancer	8.5e-05	0.00202	CcSEcCtD
Erlotinib—Infestation—Epirubicin—bone cancer	8.45e-05	0.00201	CcSEcCtD
Erlotinib—Infestation NOS—Epirubicin—bone cancer	8.45e-05	0.00201	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Epirubicin—bone cancer	8.38e-05	0.002	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—bone cancer	8.31e-05	0.00198	CcSEcCtD
Erlotinib—Body temperature increased—Cisplatin—bone cancer	8.3e-05	0.00198	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—bone cancer	8.28e-05	0.00197	CcSEcCtD
Erlotinib—Stomatitis—Epirubicin—bone cancer	8.24e-05	0.00196	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—bone cancer	8.21e-05	0.00196	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—bone cancer	8.2e-05	0.00195	CcSEcCtD
Erlotinib—Haemoglobin—Methotrexate—bone cancer	8.15e-05	0.00194	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—bone cancer	8.11e-05	0.00193	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—bone cancer	8.11e-05	0.00193	CcSEcCtD
Erlotinib—Urinary tract disorder—Methotrexate—bone cancer	8.01e-05	0.00191	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—bone cancer	7.99e-05	0.0019	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—bone cancer	7.97e-05	0.0019	CcSEcCtD
Erlotinib—Urethral disorder—Methotrexate—bone cancer	7.95e-05	0.00189	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—bone cancer	7.93e-05	0.00189	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—bone cancer	7.86e-05	0.00187	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—bone cancer	7.82e-05	0.00186	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—bone cancer	7.82e-05	0.00186	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—bone cancer	7.75e-05	0.00185	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—bone cancer	7.69e-05	0.00183	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—bone cancer	7.66e-05	0.00183	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—bone cancer	7.66e-05	0.00183	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—bone cancer	7.63e-05	0.00182	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—bone cancer	7.62e-05	0.00182	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—bone cancer	7.6e-05	0.00181	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—bone cancer	7.59e-05	0.00181	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—bone cancer	7.59e-05	0.00181	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—bone cancer	7.58e-05	0.0018	CcSEcCtD
Erlotinib—Asthenia—Cisplatin—bone cancer	7.53e-05	0.00179	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—bone cancer	7.49e-05	0.00178	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—bone cancer	7.46e-05	0.00178	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—bone cancer	7.44e-05	0.00177	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—bone cancer	7.4e-05	0.00176	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—bone cancer	7.38e-05	0.00176	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—bone cancer	7.31e-05	0.00174	CcSEcCtD
Erlotinib—Chills—Methotrexate—bone cancer	7.27e-05	0.00173	CcSEcCtD
Erlotinib—Diarrhoea—Cisplatin—bone cancer	7.18e-05	0.00171	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—bone cancer	7.17e-05	0.00171	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—bone cancer	7.16e-05	0.00171	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—bone cancer	7.1e-05	0.00169	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—bone cancer	7.09e-05	0.00169	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—bone cancer	7.06e-05	0.00168	CcSEcCtD
Erlotinib—Erythema—Methotrexate—bone cancer	7.06e-05	0.00168	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—bone cancer	7.06e-05	0.00168	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—bone cancer	7.02e-05	0.00167	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—bone cancer	7.02e-05	0.00167	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—bone cancer	6.93e-05	0.00165	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—bone cancer	6.9e-05	0.00164	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—bone cancer	6.88e-05	0.00164	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—bone cancer	6.84e-05	0.00163	CcSEcCtD
Erlotinib—Back pain—Methotrexate—bone cancer	6.83e-05	0.00163	CcSEcCtD
Erlotinib—Chills—Epirubicin—bone cancer	6.81e-05	0.00162	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—bone cancer	6.78e-05	0.00161	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—bone cancer	6.7e-05	0.0016	CcSEcCtD
Erlotinib—Vomiting—Cisplatin—bone cancer	6.67e-05	0.00159	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—bone cancer	6.65e-05	0.00158	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—bone cancer	6.64e-05	0.00158	CcSEcCtD
Erlotinib—Rash—Cisplatin—bone cancer	6.62e-05	0.00158	CcSEcCtD
Erlotinib—Dermatitis—Cisplatin—bone cancer	6.61e-05	0.00157	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—bone cancer	6.6e-05	0.00157	CcSEcCtD
Erlotinib—Erythema—Epirubicin—bone cancer	6.6e-05	0.00157	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—bone cancer	6.56e-05	0.00156	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—bone cancer	6.51e-05	0.00155	CcSEcCtD
Erlotinib—Back pain—Epirubicin—bone cancer	6.39e-05	0.00152	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—bone cancer	6.33e-05	0.00151	CcSEcCtD
Erlotinib—Chills—Doxorubicin—bone cancer	6.3e-05	0.0015	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—bone cancer	6.27e-05	0.00149	CcSEcCtD
Erlotinib—Nausea—Cisplatin—bone cancer	6.23e-05	0.00148	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—bone cancer	6.2e-05	0.00148	CcSEcCtD
Erlotinib—ORM1—vertebral column—bone cancer	6.2e-05	0.119	CbGeAlD
Erlotinib—Cough—Methotrexate—bone cancer	6.16e-05	0.00147	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—bone cancer	6.15e-05	0.00146	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—bone cancer	6.11e-05	0.00146	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—bone cancer	6.11e-05	0.00146	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—bone cancer	6.02e-05	0.00143	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—bone cancer	6.01e-05	0.00143	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—bone cancer	6.01e-05	0.00143	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—bone cancer	6.01e-05	0.00143	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	5.97e-05	0.00142	CcSEcCtD
Erlotinib—Syncope—Epirubicin—bone cancer	5.92e-05	0.00141	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—bone cancer	5.91e-05	0.00141	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—bone cancer	5.8e-05	0.00138	CcSEcCtD
Erlotinib—Cough—Epirubicin—bone cancer	5.76e-05	0.00137	CcSEcCtD
Erlotinib—Infection—Methotrexate—bone cancer	5.72e-05	0.00136	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—bone cancer	5.65e-05	0.00135	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—bone cancer	5.64e-05	0.00134	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—bone cancer	5.62e-05	0.00134	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—bone cancer	5.62e-05	0.00134	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—bone cancer	5.62e-05	0.00134	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—bone cancer	5.6e-05	0.00133	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—bone cancer	5.59e-05	0.00133	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	5.58e-05	0.00133	CcSEcCtD
Erlotinib—Anorexia—Methotrexate—bone cancer	5.49e-05	0.00131	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—bone cancer	5.48e-05	0.00131	CcSEcCtD
Erlotinib—Oedema—Epirubicin—bone cancer	5.39e-05	0.00128	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—bone cancer	5.37e-05	0.00128	CcSEcCtD
Erlotinib—Infection—Epirubicin—bone cancer	5.35e-05	0.00128	CcSEcCtD
Erlotinib—Cough—Doxorubicin—bone cancer	5.33e-05	0.00127	CcSEcCtD
Erlotinib—Shock—Epirubicin—bone cancer	5.3e-05	0.00126	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—bone cancer	5.29e-05	0.00126	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—bone cancer	5.28e-05	0.00126	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—bone cancer	5.25e-05	0.00125	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—bone cancer	5.24e-05	0.00125	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—bone cancer	5.21e-05	0.00124	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—bone cancer	5.2e-05	0.00124	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—bone cancer	5.2e-05	0.00124	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—bone cancer	5.2e-05	0.00124	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—bone cancer	5.18e-05	0.00123	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	5.17e-05	0.00123	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—bone cancer	5.14e-05	0.00122	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—bone cancer	5.13e-05	0.00122	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—bone cancer	5.07e-05	0.00121	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—bone cancer	5.01e-05	0.00119	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—bone cancer	4.99e-05	0.00119	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—bone cancer	4.97e-05	0.00118	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—bone cancer	4.97e-05	0.00118	CcSEcCtD
Erlotinib—Infection—Doxorubicin—bone cancer	4.95e-05	0.00118	CcSEcCtD
Erlotinib—Pain—Methotrexate—bone cancer	4.93e-05	0.00117	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—bone cancer	4.91e-05	0.00117	CcSEcCtD
Erlotinib—Shock—Doxorubicin—bone cancer	4.91e-05	0.00117	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—bone cancer	4.89e-05	0.00116	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—bone cancer	4.88e-05	0.00116	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—bone cancer	4.87e-05	0.00116	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—bone cancer	4.84e-05	0.00115	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—bone cancer	4.81e-05	0.00114	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—bone cancer	4.75e-05	0.00113	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—bone cancer	4.74e-05	0.00113	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—bone cancer	4.71e-05	0.00112	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—bone cancer	4.69e-05	0.00112	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—bone cancer	4.65e-05	0.00111	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—bone cancer	4.65e-05	0.00111	CcSEcCtD
Erlotinib—Constipation—Epirubicin—bone cancer	4.61e-05	0.0011	CcSEcCtD
Erlotinib—Pain—Epirubicin—bone cancer	4.61e-05	0.0011	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—bone cancer	4.55e-05	0.00108	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—bone cancer	4.55e-05	0.00108	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—bone cancer	4.54e-05	0.00108	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—bone cancer	4.51e-05	0.00107	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—bone cancer	4.45e-05	0.00106	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—bone cancer	4.41e-05	0.00105	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—bone cancer	4.39e-05	0.00105	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—bone cancer	4.34e-05	0.00103	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—bone cancer	4.31e-05	0.00103	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—bone cancer	4.3e-05	0.00102	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—bone cancer	4.26e-05	0.00102	CcSEcCtD
Erlotinib—Pain—Doxorubicin—bone cancer	4.26e-05	0.00102	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—bone cancer	4.26e-05	0.00101	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—bone cancer	4.26e-05	0.00101	CcSEcCtD
Erlotinib—Asthenia—Methotrexate—bone cancer	4.13e-05	0.000984	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—bone cancer	4.08e-05	0.000971	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—bone cancer	4.07e-05	0.000971	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—bone cancer	3.94e-05	0.000939	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—bone cancer	3.94e-05	0.000939	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—bone cancer	3.94e-05	0.000939	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—bone cancer	3.87e-05	0.000921	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—bone cancer	3.81e-05	0.000908	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—bone cancer	3.81e-05	0.000907	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—bone cancer	3.69e-05	0.000878	CcSEcCtD
Erlotinib—Vomiting—Methotrexate—bone cancer	3.66e-05	0.000872	CcSEcCtD
Erlotinib—Rash—Methotrexate—bone cancer	3.63e-05	0.000865	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—bone cancer	3.63e-05	0.000864	CcSEcCtD
Erlotinib—Headache—Methotrexate—bone cancer	3.61e-05	0.000859	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—bone cancer	3.58e-05	0.000852	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—bone cancer	3.56e-05	0.000849	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—bone cancer	3.53e-05	0.00084	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—bone cancer	3.43e-05	0.000816	CcSEcCtD
Erlotinib—Nausea—Methotrexate—bone cancer	3.42e-05	0.000815	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—bone cancer	3.41e-05	0.000813	CcSEcCtD
Erlotinib—JAK3—connective tissue—bone cancer	3.41e-05	0.0653	CbGeAlD
Erlotinib—Rash—Epirubicin—bone cancer	3.4e-05	0.000809	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—bone cancer	3.4e-05	0.000809	CcSEcCtD
Erlotinib—Headache—Epirubicin—bone cancer	3.38e-05	0.000804	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—bone cancer	3.3e-05	0.000786	CcSEcCtD
Erlotinib—Nausea—Epirubicin—bone cancer	3.2e-05	0.000763	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—bone cancer	3.17e-05	0.000755	CcSEcCtD
Erlotinib—Rash—Doxorubicin—bone cancer	3.14e-05	0.000749	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—bone cancer	3.14e-05	0.000748	CcSEcCtD
Erlotinib—Headache—Doxorubicin—bone cancer	3.12e-05	0.000744	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—bone cancer	2.96e-05	0.000706	CcSEcCtD
Erlotinib—FLT3—connective tissue—bone cancer	2.69e-05	0.0515	CbGeAlD
Erlotinib—AURKC—tendon—bone cancer	2.53e-05	0.0484	CbGeAlD
Erlotinib—TNK1—tendon—bone cancer	2.15e-05	0.0412	CbGeAlD
Erlotinib—FLT3—bone marrow—bone cancer	1.79e-05	0.0343	CbGeAlD
Erlotinib—ABL2—tendon—bone cancer	1.77e-05	0.0338	CbGeAlD
Erlotinib—MKNK1—Signaling Pathways—IL3—bone cancer	1.69e-05	0.000399	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.67e-05	0.000395	CbGpPWpGaD
Erlotinib—PIP4K2C—tendon—bone cancer	1.67e-05	0.032	CbGeAlD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.65e-05	0.000389	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—JUN—bone cancer	1.63e-05	0.000385	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—MDM2—bone cancer	1.62e-05	0.000382	CbGpPWpGaD
Erlotinib—PIP4K2C—bone marrow—bone cancer	1.62e-05	0.031	CbGeAlD
Erlotinib—EGFR—Signaling by GPCR—GRM1—bone cancer	1.61e-05	0.000381	CbGpPWpGaD
Erlotinib—PIP4K2C—spinal cord—bone cancer	1.61e-05	0.0308	CbGeAlD
Erlotinib—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	1.6e-05	0.000377	CbGpPWpGaD
Erlotinib—ULK3—tendon—bone cancer	1.6e-05	0.0305	CbGeAlD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—EGFR—bone cancer	1.59e-05	0.000375	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.59e-05	0.000375	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—JUN—bone cancer	1.59e-05	0.000374	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—GSTP1—bone cancer	1.58e-05	0.000374	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—CYP3A4—bone cancer	1.57e-05	0.00037	CbGpPWpGaD
Erlotinib—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	1.56e-05	0.000369	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NDUFA12—bone cancer	1.56e-05	0.000369	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	1.55e-05	0.000366	CbGpPWpGaD
Erlotinib—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	1.55e-05	0.000365	CbGpPWpGaD
Erlotinib—ULK3—bone marrow—bone cancer	1.55e-05	0.0296	CbGeAlD
Erlotinib—ULK3—spinal cord—bone cancer	1.54e-05	0.0294	CbGeAlD
Erlotinib—JAK3—Signaling Pathways—SMO—bone cancer	1.54e-05	0.000362	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	1.52e-05	0.000359	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—EGFR—bone cancer	1.52e-05	0.000358	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—ATF1—bone cancer	1.52e-05	0.000358	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KIT—bone cancer	1.51e-05	0.000357	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	1.51e-05	0.000357	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.51e-05	0.000356	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—EGFR—bone cancer	1.5e-05	0.000354	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.48e-05	0.00035	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NDUFA12—bone cancer	1.48e-05	0.000348	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—EGFR—bone cancer	1.47e-05	0.000347	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MET—bone cancer	1.45e-05	0.000343	CbGpPWpGaD
Erlotinib—MKNK1—bone marrow—bone cancer	1.45e-05	0.0278	CbGeAlD
Erlotinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—bone cancer	1.45e-05	0.000342	CbGpPWpGaD
Erlotinib—MKNK1—spinal cord—bone cancer	1.45e-05	0.0277	CbGeAlD
Erlotinib—MKNK1—Signaling Pathways—TGFBR2—bone cancer	1.44e-05	0.000341	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—JUN—bone cancer	1.44e-05	0.000339	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.43e-05	0.000338	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—BRAF—bone cancer	1.42e-05	0.000336	CbGpPWpGaD
Erlotinib—SLK—tendon—bone cancer	1.42e-05	0.0272	CbGeAlD
Erlotinib—ABL1—Axon guidance—MMP2—bone cancer	1.42e-05	0.000335	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	1.42e-05	0.000334	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	1.42e-05	0.000334	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KIT—bone cancer	1.41e-05	0.000332	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—GNA11—bone cancer	1.4e-05	0.000331	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TP53—bone cancer	1.39e-05	0.000328	CbGpPWpGaD
Erlotinib—SLK—bone marrow—bone cancer	1.38e-05	0.0264	CbGeAlD
Erlotinib—SLK—spinal cord—bone cancer	1.37e-05	0.0262	CbGeAlD
Erlotinib—MKNK1—Signaling Pathways—IGF1R—bone cancer	1.36e-05	0.000321	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NDUFA12—bone cancer	1.35e-05	0.000319	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NDUFA12—bone cancer	1.34e-05	0.000317	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—GSTP1—bone cancer	1.34e-05	0.000317	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—TP53—bone cancer	1.33e-05	0.000315	CbGpPWpGaD
Erlotinib—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	1.32e-05	0.000312	CbGpPWpGaD
Erlotinib—MKNK1—Disease—BRAF—bone cancer	1.32e-05	0.000312	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.32e-05	0.000311	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ATF1—bone cancer	1.31e-05	0.000308	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.3e-05	0.000307	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NT5C3A—bone cancer	1.29e-05	0.000305	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL3—bone cancer	1.27e-05	0.000301	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TP53—bone cancer	1.27e-05	0.000301	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—PLAU—bone cancer	1.26e-05	0.000298	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SMO—bone cancer	1.25e-05	0.000295	CbGpPWpGaD
Erlotinib—ABL1—connective tissue—bone cancer	1.24e-05	0.0237	CbGeAlD
Erlotinib—STK10—tendon—bone cancer	1.24e-05	0.0237	CbGeAlD
Erlotinib—CYP1A1—Metabolism—NT5C3A—bone cancer	1.22e-05	0.000289	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—CDK4—bone cancer	1.21e-05	0.000287	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MET—bone cancer	1.21e-05	0.000287	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MMP2—bone cancer	1.21e-05	0.000286	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—bone cancer	1.21e-05	0.000286	CbGpPWpGaD
Erlotinib—STK10—bone marrow—bone cancer	1.2e-05	0.0229	CbGeAlD
Erlotinib—EGFR—Signaling by NGF—MDM2—bone cancer	1.19e-05	0.000281	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NDUFA12—bone cancer	1.18e-05	0.000278	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KIT—bone cancer	1.15e-05	0.000271	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—GNA11—bone cancer	1.14e-05	0.00027	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SPARC—bone cancer	1.14e-05	0.000269	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—bone cancer	1.14e-05	0.000269	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—SMO—bone cancer	1.14e-05	0.000268	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	1.12e-05	0.000265	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NT5C3A—bone cancer	1.12e-05	0.000265	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NT5C3A—bone cancer	1.11e-05	0.000263	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NDUFA12—bone cancer	1.11e-05	0.000262	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MDM2—bone cancer	1.11e-05	0.000262	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.11e-05	0.000261	CbGpPWpGaD
Erlotinib—MAP2K5—tendon—bone cancer	1.1e-05	0.0211	CbGeAlD
Erlotinib—EGFR—Signaling Pathways—RGS1—bone cancer	1.1e-05	0.00026	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GRM4—bone cancer	1.1e-05	0.00026	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TGFBR2—bone cancer	1.09e-05	0.000257	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PTGS2—bone cancer	1.07e-05	0.000252	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—MMP9—bone cancer	1.07e-05	0.000252	CbGpPWpGaD
Erlotinib—MAP2K5—spinal cord—bone cancer	1.06e-05	0.0204	CbGeAlD
Erlotinib—MAP2K5—Signaling Pathways—ATF1—bone cancer	1.06e-05	0.000251	CbGpPWpGaD
Erlotinib—CYP1B1—connective tissue—bone cancer	1.05e-05	0.0201	CbGeAlD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—bone cancer	1.05e-05	0.000247	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—GNA11—bone cancer	1.04e-05	0.000246	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—GNA11—bone cancer	1.04e-05	0.000245	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MET—bone cancer	1.04e-05	0.000245	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CDK4—bone cancer	1.04e-05	0.000245	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL3—bone cancer	1.04e-05	0.000245	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.04e-05	0.000245	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ATF1—bone cancer	1.03e-05	0.000244	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IGF1R—bone cancer	1.02e-05	0.000242	CbGpPWpGaD
Erlotinib—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.02e-05	0.000241	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP2—bone cancer	1.01e-05	0.000239	CbGpPWpGaD
Erlotinib—EGFR—Disease—ENO2—bone cancer	1.01e-05	0.000239	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KIT—bone cancer	1.01e-05	0.000238	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL3—bone cancer	1.01e-05	0.000238	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—bone cancer	9.9e-06	0.000234	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KIT—bone cancer	9.85e-06	0.000233	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NT5C3A—bone cancer	9.76e-06	0.00023	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GRM1—bone cancer	9.53e-06	0.000225	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL3—bone cancer	9.46e-06	0.000223	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	9.44e-06	0.000223	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL3—bone cancer	9.43e-06	0.000223	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NDUFA12—bone cancer	9.41e-06	0.000222	CbGpPWpGaD
Erlotinib—EGFR—Disease—DHFR—bone cancer	9.39e-06	0.000222	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ENO2—bone cancer	9.32e-06	0.00022	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—BRAF—bone cancer	9.26e-06	0.000219	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NT5C3A—bone cancer	9.2e-06	0.000217	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MMP9—bone cancer	9.12e-06	0.000215	CbGpPWpGaD
Erlotinib—JAK3—Immune System—MDM2—bone cancer	9.05e-06	0.000214	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TGFBR2—bone cancer	8.88e-06	0.00021	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ATF1—bone cancer	8.83e-06	0.000208	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ENO2—bone cancer	8.69e-06	0.000205	CbGpPWpGaD
Erlotinib—ORM1—bone marrow—bone cancer	8.68e-06	0.0166	CbGeAlD
Erlotinib—EGFR—Developmental Biology—MMP2—bone cancer	8.66e-06	0.000204	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—DHFR—bone cancer	8.65e-06	0.000204	CbGpPWpGaD
Erlotinib—ORM1—spinal cord—bone cancer	8.65e-06	0.0165	CbGeAlD
Erlotinib—EGFR—Innate Immune System—KIT—bone cancer	8.63e-06	0.000204	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—EGFR—bone cancer	8.63e-06	0.000204	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL3—bone cancer	8.61e-06	0.000203	CbGpPWpGaD
Erlotinib—SLCO2B1—tendon—bone cancer	8.59e-06	0.0164	CbGeAlD
Erlotinib—ABL1—tendon—bone cancer	8.52e-06	0.0163	CbGeAlD
Erlotinib—MAP2K5—Signaling Pathways—IGF1R—bone cancer	8.35e-06	0.000197	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	8.31e-06	0.000196	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KIT—bone cancer	8.29e-06	0.000196	CbGpPWpGaD
Erlotinib—SLCO2B1—spinal cord—bone cancer	8.29e-06	0.0159	CbGeAlD
Erlotinib—ABL1—bone marrow—bone cancer	8.25e-06	0.0158	CbGeAlD
Erlotinib—ABL1—spinal cord—bone cancer	8.21e-06	0.0157	CbGeAlD
Erlotinib—UGT1A1—Metabolism—GNA11—bone cancer	8.08e-06	0.000191	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—DHFR—bone cancer	8.07e-06	0.00019	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	8.01e-06	0.000189	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MDM2—bone cancer	7.95e-06	0.000188	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ENO2—bone cancer	7.91e-06	0.000187	CbGpPWpGaD
Erlotinib—JAK3—Immune System—JUN—bone cancer	7.87e-06	0.000186	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NT5C3A—bone cancer	7.79e-06	0.000184	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MDM2—bone cancer	7.76e-06	0.000183	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP9—bone cancer	7.62e-06	0.00018	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EGFR—bone cancer	7.57e-06	0.000179	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GNA11—bone cancer	7.54e-06	0.000178	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KIT—bone cancer	7.43e-06	0.000175	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—DHFR—bone cancer	7.34e-06	0.000173	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CYP3A4—bone cancer	7.33e-06	0.000173	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NDUFA12—bone cancer	7.26e-06	0.000171	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	7.22e-06	0.00017	CbGpPWpGaD
Erlotinib—CYP1B1—tendon—bone cancer	7.21e-06	0.0138	CbGeAlD
Erlotinib—JAK3—Signaling Pathways—BRAF—bone cancer	6.98e-06	0.000165	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—JUN—bone cancer	6.91e-06	0.000163	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GNA11—bone cancer	6.86e-06	0.000162	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CYP3A4—bone cancer	6.83e-06	0.000161	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFBR2—bone cancer	6.8e-06	0.000161	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.8e-06	0.000161	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MDM2—bone cancer	6.8e-06	0.00016	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—EGFR—bone cancer	6.77e-06	0.00016	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—JUN—bone cancer	6.74e-06	0.000159	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SMO—bone cancer	6.72e-06	0.000159	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MMP9—bone cancer	6.56e-06	0.000155	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—MDM2—bone cancer	6.53e-06	0.000154	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP9—bone cancer	6.51e-06	0.000154	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GSTP1—bone cancer	6.27e-06	0.000148	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP3A4—bone cancer	6.22e-06	0.000147	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PLAU—bone cancer	6.21e-06	0.000147	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EGFR—bone cancer	6.18e-06	0.000146	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EGFR—bone cancer	6.16e-06	0.000145	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GNA11—bone cancer	6.14e-06	0.000145	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KIT—bone cancer	6.06e-06	0.000143	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NT5C3A—bone cancer	6.02e-06	0.000142	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—JUN—bone cancer	5.91e-06	0.000139	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KIT—bone cancer	5.88e-06	0.000139	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MDM2—bone cancer	5.85e-06	0.000138	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GSTP1—bone cancer	5.85e-06	0.000138	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ATF1—bone cancer	5.71e-06	0.000135	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—BRAF—bone cancer	5.69e-06	0.000134	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	5.68e-06	0.000134	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ENO2—bone cancer	5.67e-06	0.000134	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL3—bone cancer	5.57e-06	0.000131	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EGFR—bone cancer	5.44e-06	0.000128	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ENO2—bone cancer	5.35e-06	0.000126	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSTP1—bone cancer	5.32e-06	0.000126	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EGFR—bone cancer	5.3e-06	0.000125	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—DHFR—bone cancer	5.26e-06	0.000124	CbGpPWpGaD
Erlotinib—ABCG2—bone marrow—bone cancer	5.2e-06	0.00996	CbGeAlD
Erlotinib—ABCG2—spinal cord—bone cancer	5.18e-06	0.00991	CbGeAlD
Erlotinib—JAK3—Signaling Pathways—JUN—bone cancer	5.09e-06	0.00012	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—bone cancer	5.07e-06	0.00012	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KIT—bone cancer	5.03e-06	0.000119	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—DHFR—bone cancer	4.97e-06	0.000117	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MMP9—bone cancer	4.95e-06	0.000117	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GNA11—bone cancer	4.91e-06	0.000116	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ENO2—bone cancer	4.91e-06	0.000116	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ENO2—bone cancer	4.88e-06	0.000115	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MDM2—bone cancer	4.77e-06	0.000113	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.77e-06	0.000113	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFBR2—bone cancer	4.76e-06	0.000112	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GNA11—bone cancer	4.64e-06	0.00011	CbGpPWpGaD
Erlotinib—EGFR—Disease—KIT—bone cancer	4.64e-06	0.00011	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MDM2—bone cancer	4.63e-06	0.000109	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—DHFR—bone cancer	4.55e-06	0.000107	CbGpPWpGaD
Erlotinib—ALB—Metabolism—DHFR—bone cancer	4.53e-06	0.000107	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1R—bone cancer	4.48e-06	0.000106	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP3A4—bone cancer	4.46e-06	0.000105	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—bone cancer	4.45e-06	0.000105	CbGpPWpGaD
Erlotinib—EGFR—Disease—BRAF—bone cancer	4.36e-06	0.000103	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ENO2—bone cancer	4.28e-06	0.000101	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GNA11—bone cancer	4.26e-06	0.0001	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GNA11—bone cancer	4.23e-06	9.99e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP3A4—bone cancer	4.21e-06	9.94e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.19e-06	9.88e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—JUN—bone cancer	4.15e-06	9.79e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MMP9—bone cancer	4.03e-06	9.52e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ENO2—bone cancer	4.03e-06	9.51e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—JUN—bone cancer	4.03e-06	9.51e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—bone cancer	4e-06	9.44e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—DHFR—bone cancer	3.97e-06	9.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MDM2—bone cancer	3.96e-06	9.35e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP3A4—bone cancer	3.86e-06	9.11e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.84e-06	9.06e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP3A4—bone cancer	3.84e-06	9.06e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.82e-06	9.01e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTP1—bone cancer	3.81e-06	8.99e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—DHFR—bone cancer	3.74e-06	8.83e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GNA11—bone cancer	3.71e-06	8.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MDM2—bone cancer	3.66e-06	8.63e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTP1—bone cancer	3.6e-06	8.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—bone cancer	3.52e-06	8.32e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GNA11—bone cancer	3.49e-06	8.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—JUN—bone cancer	3.44e-06	8.12e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ENO2—bone cancer	3.41e-06	8.06e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP3A4—bone cancer	3.36e-06	7.94e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—bone cancer	3.36e-06	7.93e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTP1—bone cancer	3.3e-06	7.79e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTP1—bone cancer	3.28e-06	7.75e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—bone cancer	3.26e-06	7.69e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KIT—bone cancer	3.25e-06	7.67e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—bone cancer	3.25e-06	7.66e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP3A4—bone cancer	3.17e-06	7.48e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—DHFR—bone cancer	3.17e-06	7.48e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—bone cancer	3.17e-06	7.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BRAF—bone cancer	3.06e-06	7.21e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—bone cancer	3.03e-06	7.15e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GNA11—bone cancer	2.96e-06	6.99e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—bone cancer	2.88e-06	6.79e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—bone cancer	2.76e-06	6.5e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—bone cancer	2.74e-06	6.46e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—bone cancer	2.71e-06	6.4e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP3A4—bone cancer	2.68e-06	6.33e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.67e-06	6.3e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO2—bone cancer	2.63e-06	6.22e-05	CbGpPWpGaD
Erlotinib—ABCB1—bone marrow—bone cancer	2.57e-06	0.00491	CbGeAlD
Erlotinib—EGFR—Signaling Pathways—MDM2—bone cancer	2.56e-06	6.04e-05	CbGpPWpGaD
Erlotinib—ABCB1—spinal cord—bone cancer	2.55e-06	0.00489	CbGeAlD
Erlotinib—ALB—Hemostasis—TP53—bone cancer	2.5e-06	5.89e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—DHFR—bone cancer	2.44e-06	5.77e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—bone cancer	2.3e-06	5.42e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GNA11—bone cancer	2.28e-06	5.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JUN—bone cancer	2.22e-06	5.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—bone cancer	2.16e-06	5.11e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—bone cancer	1.97e-06	4.66e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—bone cancer	1.86e-06	4.4e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—bone cancer	1.77e-06	4.18e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—bone cancer	1.71e-06	4.04e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—bone cancer	1.7e-06	4.01e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—bone cancer	1.49e-06	3.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—bone cancer	1.47e-06	3.47e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—bone cancer	1.4e-06	3.31e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—bone cancer	1.19e-06	2.81e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—bone cancer	9.18e-07	2.17e-05	CbGpPWpGaD
